Print

MDS Nordion (MDZ) Release: New European Study Shows TheraSphere(R) Prolongs Liver Cancer Survival Rates  
10/7/2010 10:10:33 AM

OTTAWA, Canada--(BUSINESS WIRE)--MDS Nordion, a leading provider of products and services to the global health science market, today announced that the first large European study using Yttrium-90 (Y-90) glass microspheres has been published on the use of TheraSphere®, an innovative radioembolisation therapy for the localised treatment of patients with advanced hepatocellular carcinoma (HCC) or primary liver cancer. The publication, which currently can be viewed online and is expected to appear in the November 2010 edition of Hepatology, concludes that radioembolisation with TheraSphere® is both safe and effective, and states that the overall survival rate is similar to that found in another recently published large study analysing Y-90 glass microspheres for the treatment of HCC.1
//-->